Myocardial collagen turnover in hypertrophic cardiomyopathy

Circulation

Volumn 108, Issue 12, 2003, Pages 1455-1460

  Lombardi, Raffaella ^b   Betocchi, Sandro ^a   Losi, Maria Angela ^b   Tocchetti, Carlo Gabriele ^b   Aversa, Mariano ^b   Miranda, Marianna ^b   D'Alessandro, Gianluigi ^b   Cacace, Alessandra ^b   Ciampi, Quirino ^b   Chiariello, Massimo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

Cardiomyopathy; Collagen; Diastole; Metalloproteinases; Peptides

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PRIORITY JOURNAL; PULMONARY VEIN; RADIOIMMUNOASSAY;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; COLLAGEN; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIUM; PEPTIDE FRAGMENTS; PROCOLLAGEN; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR FUNCTION, LEFT;

EID: 0141727726     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000090687.97972.10     Document Type: Article

References (32)

1. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780-844.
2. Shirani J, Pick R, Roberts WC, et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35: 36-44.
3. Pardo-Mindan JF, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J. 1993:14(suppl J):12-14.
4. Varnava AM, Elliott PM, Sharma S, et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476-482.
5. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105: 2512-2517.
6. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242-1244.
7. Diez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Rev Cardiovasc Res. 1997;35:202-205.
8. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46:214-224.
9. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
10. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation. 1987;75(suppl 1):I-26-I-33.
11. Spirito P, Maron BJ, Chiarella F, et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. Circulation. 1985;72:310-316.
12. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985;1:1-83.
13. Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation. 1999;99:254-261.
14. Panza JA, Petrone RK, Fananapazir L, et al. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;19:91-99.
15. Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation. 1987;75: 175-183.
16. Melkko J, Niemi S, Risteli L, et al. Radioimmunoassay of the carboxy-terminal propeptide of human type I procollagen. Clin Chem. 1990;36: 1328-1332.
17. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 2002;27:92-98.
18. Briguori C, Belocchi S, Romano M, et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. Am J Cardiol. 1999;84:309-315.
19. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses mycardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791.
20. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104:317-324.
21. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophie cardiomyopathy. Lancet. 2000;355:58-60.
22. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535-538.
23. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of collagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.
24. Lopez B, Querejela R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type 1 in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-291.
25. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.
26. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension. 2002; 40:136-141.
27. Cuda G, Fananapair L, Zhu W, et al. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J Clin Invest. 1993;91:2861-2865.
28. Schwartzkopff B, Fassbach M, Pelzer B, et al. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail. 2002;4:439-444.
29. Walther T, Schubert A, Falk V, et al. Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation. 2001; 104(suppl I):I-54-I-58.
30. Manganelli F, Betocchi S, Losi MA, et al. Influence of left ventricular cavity size on clinical presentation in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:547-552.
31. Betocchi S, Hess OM, Losi MA, et al. Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation. 1993;88:2206-2219.
32. Krayenbuehl HP, Hess OM, Monrad ES, et al. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation. 1989;79:744-755.